000			01858 a2200553 4500
005			20250511205834.0
264		0	_c19911218
008			199112s 0 0 eng d
022			_a0344-5704
024	7		_a10.1007/BF00685825 _2doi
040			_aNLM _beng _cNLM
100	1		_aSagrada, A
245	0	0	_aAntiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. _h[electronic resource]
260			_bCancer chemotherapy and pharmacology _c1991
300			_a470-4 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article
650	0	4	_aAnimals
650	0	4	_aAntiemetics _xtherapeutic use
650	0	4	_aBenzimidazoles _xtherapeutic use
650	0	4	_aBridged Bicyclo Compounds _xtherapeutic use
650	0	4	_aBridged Bicyclo Compounds, Heterocyclic
650	0	4	_aCisplatin _xadverse effects
650	0	4	_aDisease Models, Animal
650	0	4	_aDogs
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDoxorubicin _xadverse effects
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aFemale
650	0	4	_aFerrets
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMetoclopramide _xtherapeutic use
650	0	4	_aNeoplasms, Experimental _xcomplications
650	0	4	_aOndansetron
650	0	4	_aSerotonin Antagonists _xtherapeutic use
650	0	4	_aTime Factors
650	0	4	_aVomiting _xetiology
700	1		_aTurconi, M
700	1		_aBonali, P
700	1		_aSchiantarelli, P
700	1		_aMicheletti, R
700	1		_aMontagna, E
700	1		_aNicola, M
700	1		_aAlgate, D R
700	1		_aRimoldi, E M
700	1		_aDonetti, A
773	0		_tCancer chemotherapy and pharmacology _gvol. 28 _gno. 6 _gp. 470-4
856	4	0	_uhttps://doi.org/10.1007/BF00685825 _zAvailable from publisher's website
999			_c1840564 _d1840564